Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis

Inclusion Criteria: * \- Male or female at least 18 years of age * \- A diagnosis of ESKD undergoing maintenance dialysis for at least 12 weeks * \- Serum hs-CRP ≥ 2.0 mg/L * \- A diagnosis of diabetes mellitus OR ASCVD Exclusion Criteria: * \- Subjects who participated in Part 1 (phase 2b) are not eligible to participate in Part 2 (phase 3) * \- Concomitant use of systemic immunosuppressant drugs * \- Abnormal LFTs * \- Any life-threatening disease expected to result in death within 12 months * \- A history of GI perforation, inflammatory bowel disease (except fully excised ulcerative colitis), or peptic ulcer disease * -Clinically significant active infection or history of opportunistic or invasive fungal infection